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Irritable bowel syndrome (IBS) accounts for 25% of gastroenterology output practice, making it one of the most common
disorders in this practice. Psychological and social factors may aﬀect the development of this chronic disorder. Furthermore,
psychiatric symptoms and psychiatric diseases are highly prevalent in this condition, but the approach to treating these is not
always straightforward. As emphasized in the biopsychosocial model of IBS, with regard to the modulatory role of stress-related
brain-gut interactions and association of the disease with psychological factors and emotional state, it proves useful to encourage
psychopharmacological treatments and psychosocial therapies, both aiming at reducing stress perception. The aim of this paper is
to analyze the eﬀectiveness of psychopharmacological treatment and psychological interventions on irritable bowel syndrome.
1. Introduction
Irritable bowel syndrome (IBS) is a chronic, relapsing, and
remitting functional disorder of the gastrointestinal (GI)
tract for which there is no known structural or anatomical
explanation.
Its prevalence in the general population is estimated to
be between 5% and 20% [1–4], accounting for up to 25%
of gastroenterology output practice [5]. The presence of IBS
is defined by clinical criteria, which include the presence
of abdominal pain, or discomfort, and alterations in bowel
habits, in the absence of red flag alarm features, such as
weight loss or anemia [6].
IBS is defined by the Rome III criteria as “symptoms
of recurrent abdominal pain or discomfort and a marked
change in bowel habits for at least six months, with
symptoms experienced on at least three days of at least three
months, with two of the three following findings: (a) pain is
relieved by a bowel movement; (b) onset of pain is related to
a change in frequency of stool; (c) onset of pain is related to
a change in appearance of stool” [7].
The cause of IBS is actually unknown, but probably it
is unlikely that a single factor is responsible for the diverse
presentations of this heterogeneous and complex disorder.
In fact, IBS has a multifactorial etiology, involving altered
gut reactivity and motility, altered pain perception, and
alteration of the brain-gut axis [8]. In addition, psychological
and social factors can influence digestive function, symptom
perception, illness behavior, and outcome [9]. According to
the biopsychosocial model of IBS, symptoms are both deter-
mined and modified by psychological and social influences,
and the link between psychosocial factors and GI functions
is through the brain-gut axis [10, 11].
The brain-gut axis allows bidirectional input and thus
links emotional and cognitive centers of the brain with
peripheral functioning of the GI tract and vice versa. Hence
extrinsic (vision, smell, etc.) or enteroceptive (emotion,
thought) information has, by nature of its neural con-
nections from higher centers, the capacity to aﬀect GI
sensation, motility, secretion, and inflammation. Conversely,
viscerotropic eﬀects (e.g., visceral aﬀerent communications
to the brain) reciprocally aﬀect central pain perception,
mood, and behavior [12].
Since the biopsychosocial model of IBS was developed,
there has been constantly growing interest in the influence of
psychosocial factors on the pathogenesis and clinical course
of IBS [8].
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Psychological and social factors may already aﬀect
the development of IBS early in life, conditioning one’s
psychosocial development, and during life, leading to gut
dysfunction and dysregulation of the brain-gut axis, through
the alteration of digestive functions (motility, sensation,
inflammation), symptom perception, and illness behavior
[11].
Studies about IBS clustering in families show that envi-
ronmental factors may play a role, together with inherited
mechanisms, in the development of IBS [13, 14]. A history
of abuse represents a particularly important factor leading to
increased psychological distress [15–21].
Personality traits are also implicated in the pathogenesis
of IBS and in the decision to seek medical help [8].
Neuroticism (considered as the tendency to experience
negative emotions) and alexithymia (defined as diﬃculty in
identifying feelings and distinguishing between feelings and
bodily sensations) are the most prevalent traits; furthermore,
neuroticism is a predictor of illness perception and influences
coping strategies [22–25].
Furthermore, patients with IBS often present irrational
health beliefs, leading to hypochondriac attitudes and
respond to their illness adopting diﬀerent coping strategies,
compared with patients with organic diseases or healthy
controls [26–28].
Finally, psychiatric symptoms and psychiatric diseases
are frequent in IBS, especially in severe forms. Conversely,
patients with severe IBS may have more than one psychiatric
disorder [29–32]. Particularly, depression is the most com-
mon psychiatric disorder in IBS, involving approximately
30% of patients. In this subset of patients, high levels of
somatization determine frequent use of health care services,
poor response to treatment and poor health-related quality
of life [28, 33–38].
As emphasized in the biopsychosocial model of IBS, with
regard to the modulatory role of stress-related brain-gut
interactions and its association with psychological factors
and emotional state, it proves useful to encourage psy-
chopharmacological treatments and psychosocial therapies,
both aiming at reducing stress perception. The aim of this
paper is to analyze the eﬀectiveness of psychopharmacolog-
ical treatment and psychological actions on irritable bowel
syndrome.
Figure 1 shows schematically the targets of currents and
new psychopharmacological therapies for IBS.
2. Antidepressants
Among the currently available classes of drugs for the
treatment of IBS, antidepressants are useful because of their
analgesic properties, independent of their mood-improving
eﬀects, and they may therefore be beneficial to patients with
neuropathic pain [39–42].
Long-term use of all antidepressants makes it possible to
enhance glucocorticoid signaling and to inhibit overactivity
of corticotrophin-releasing factors in the brain and presum-
ably in the periphery. Each class of antidepressants aﬀects
several transmitters via reciprocal actions between amine and
neuropeptide systems and reduces excessive cytokine release
associated with various conditions in which inflammatory
cytokines play a role [43].
Antidepressants alter receptor sensitivity, which in all
cases is believed to result in enhanced serotonin neurotrans-
mission. In particular, tricyclic antidepressants (TCADs)
increase the sensitivity of postsynaptic serotonin receptors
and downregulate alpha-2 presynaptic receptors and het-
eroreceptors; their analgesic eﬀects are also mediated by
blockage of a class of voltage-dependent sodium channels
in extrinsic sensory neurons [44]. They also antagonize
muscarinic acetylcholine receptors [45]. These antimus-
carinic eﬀects of TCADs are responsible for many of
their side eﬀects, including constipation, dry mouth, and
blurred vision [46]. However, slowing of GI transit may
be of therapeutic advantage in diarrhea-predominant IBS
[47]. In contrast, selective serotonin reuptake inhibitors
(SSRIs) and serotonin-norepinephrine reuptake inhibitors
(SNRIs) reduce the sensitivity of 5HT-1A autoreceptors and
heteroceceptors, whose downregulation is believed to play
the most important role in the antidepressant, anxiolytic,
and analgesic eﬀects of antidepressants. In this connection,
serotonin acts as a secretagogue and tends to stimulate GI
motility [46]. Thus, SSRIs could be particularly useful in
patients with constipation-predominant IBS [6].
A 2009 meta-analysis that included 13 placebo-
controlled trials of antidepressants in 789 adults with IBS
concluded that antidepressants were significantly more
eﬀective than a placebo for the relief of pain and global
symptoms (relative risk of IBS symptoms persisting 0.66,
95% CI 0.57 to 0.78) at a duration of therapy ranging from
one to three months [47]. The number needed to treat
one patient was four. The treatment eﬀects were similar
for SSRIs and TCADs. A similar conclusion was reached in
a 2009 position statement from the American College of
Gastroenterology Task Force on IBS [48].
Three further RCTs have been published since the meta-
analysis was published, but the results were conflicting, with
two demonstrating a benefit of TCADs and SSRIs [49, 50]
and a third demonstrating no benefit of SSRIs [51]. However,
when the results of these trials are incorporated into the prior
meta-analysis, the benefit of both TCADs and SSRIs remains
reassuringly similar [52].
A systematic review performed by the Cochrane Library,
and evaluating bulking agents, antispasmodics, and antide-
pressants for the treatment of IBS (but without considering
the safety of these drugs), emphasized that “antidepressants
are eﬀective for the treatment of IBS” [53], providing a
statistically significant benefit over placebo for abdominal
pain, global assessment and IBS-symptoms score. Subgroup
analyses for SSRIs and TCADs showed a statistically sig-
nificant improvement in global assessment for SSRIs and a
statistically significant improvement in abdominal pain and
symptoms score for TCADs. The authors concluded that
antidepressants could be used in patients who seek drug
therapy and who have not responded to antispasmodics, but
considering that their eﬀectiveness may vary with individual
patient features.
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Figure 1: Brain-gut axis and pharmacological approaches for irritable bowel syndrome. This figure shows schematically the targets of
the current and novel psychopharmacological therapies for irritable bowel syndrome. The reason to use these approaches is the presence
of bidirectional connections between brain and gut: according to this pathophysiological model, emotional and cognitive centers of the
brain, particularly those involving pain perception, are linked with peripheral functioning of gastrointestinal tract, and vice versa, thus,
conditioning intestinal motility, sensation, and inflammation.
With regard to the practical use of antidepressants in
IBS, improvement in neuropathic pain with TCADs occurs
at lower doses than required for treatment of depression. The
initial doses of the drugs should be administered, as a result,
at a low dosage, titrating them to pain control and tolerance.
In case of partial response to treatment, it is prudent
to increase the dose of the drug, reassessing response and
tolerability every 4–6 weeks. With an adequate dosage, some
response in the first 6–8 weeks should be apparent, but
remission can occur. If there is no response at 6 weeks, and
compliance and treatment intensity appear to be adequate,
switching to another class may obviate the need for referral
for psychiatric consultation. Whether to persist or refer
remains a clinical decision between the physician and patient.
For some patients, the use of concomitant benzodiazepines
for anxiety control may help with compliance and allows
more optimal control of symptoms [54].
In contrast, antidepressant eﬃcacy is unproven in chil-
dren, as illustrated in a multicenter trial of 83 children
with functional GI disorders, in which they were randomly
assigned to amitriptyline or a placebo for four weeks,
considering, as the primary end-point, the child’s assessment
of pain relief and sense of improvement [55]. At four weeks,
there was no significant diﬀerence between amitriptyline and
the placebo in the frequency of attaining the primary end-
point (63 versus 58 percent, P = 0.85). The authors also
noted that a longer period of treatment and a higher dose of
antidepressants may have produced diﬀerent results and that
there may be a large placebo eﬀect in children due tomultiple
factors; indeed, in another trial of 33 adolescents assigned
to amitriptyline or a placebo, the first one was eﬀective in
reducing diarrhea and pain after a longer period of treatment
[56].
This finding is also emphasized in the review performed
by the Cochrane Library, where the authors conclude that
clinicians must be aware that the existing randomized
controlled evidence is limited to studies on amitriptyline
and revealed no statistically significant diﬀerence between
amitriptyline and a placebo for most eﬃcacy outcomes
in children and adolescents. Furthermore, antidepressants
can lead to substantial, sometimes life-threatening adverse
eﬀects, and consequently, until better evidence evolves,
clinicians should weigh up the potential benefits of antide-
pressants in pediatric patients [57].
Although standard antidepressants of the tricyclic and
serotonin reuptake inhibitors classes have been assessed
in meta-analyses, as mentioned above, an example of a
novel class of centrally acting agents that has not been
assessed extensively is the atypical antipsychotic quetiapine,
which ameliorates anxiety and sleep disturbances, augments
the eﬀect of antidepressants, and provides an independent
analgesic eﬀect [58].
The use of atypical antipsychotics could be considered
in the setting of patients with severe IBS and coexistent
severe psychiatric comorbidity. In this connection, in a study
on the medical data of patients with severe refractory GI
disorders, Grover et al. [59] reported that, among the 11 of 21
patients still on the medication at followup, 6 demonstrated
global relief of symptoms and 9 were satisfied with treatment.
The other 10 patients discontinued therapy because of the
drug’s side eﬀect of somnolence or because of lack of GI
eﬃcacy. This is a very specific group of patients with known
and significant psychiatric diagnoses. This approach requires
further blind studies before it can be endorsed; physicians
without experience with this class of agents should probably
avoid prescribing them [58]. As a consequence, one should
not recommend its use until the evidence yields solid data
regarding the eﬃcacy and safety of this class of drugs.
3. Benzodiazepines
Benzodiazepines enhance the inhibitory eﬀects of gamma-
aminobutyric acid (GABA) via potentiation at the GABA-A
receptors, diminish norepinephrine neurotransmission, and
antagonize the eﬀects of cholecystokinin in the brain and gut.
This results in immediate anxiolytic activity [45].
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Patients with prominent anxiety are often intolerant
of antidepressants and can be treated with benzodiazepine
monotherapy [54].
Benzodiazepines receptors were identified in subcorti-
cal and hypothalamic regions and appear important in
controlling autonomic functions [53], such as motor and
sensory activity of the gut [60]: nevertheless they do not
exist in the gut [61]. Furthermore, benzodiazepines may
lower pain thresholds by stimulating GABA, thereby decreas-
ing brain serotonin. Animal studies on the R-enantiomer
of tofisopam (the nonsedative anxiolytic), dextofisopam,
showed encouraging results in reducing colon motility and
visceral sensitivity with little eﬀect beneath basal conditions
[62].
In a phase IIb study of dextofisopam for 12 weeks
in 140 patients with IBS, Leventer et al. observed overall
symptom relief (primary end point) in 57% of patients
as compared with placebo (43% of patients). Although
dextofisopam improved stool consistency in men and
women, the recurrence rate was only decreased in females.
This occurred within one week. The most common side
eﬀects were headache and abdominal pain (in 12% of
patients in comparison with 4% in the placebo group) which
were comparable to placebo. No benefit on bloating, partial
defecation, or hospital anxiety and depression scale scores
was observed [63].
The main disadvantage of benzodiazepines is the lack of
reliable antidepressant eﬃcacy, even if in open-label studies,
alprazolam (2–8mg/day) improves IBS in patients with panic
disorders [64]. In another study, Castedal et al. [65] showed
a slight eﬀect of midazolam on small bowel motility using
manometry; however, phase III related retroperistalsis did
not work.
Anxiolytic agents are of limited usefulness in IBS because
of the risk of drug interactions, tolerance, potential abuse,
and rebound withdrawal. They may, however, be useful for
short-term reduction of acute situational anxiety that may
be contributing to symptoms [46].
4. Future Psychopharmacological Perspectives
On the basis of the results of the clinical trials confirm-
ing the eﬀectiveness of centrally-targeted pharmacological
interventions, such as with antidepressants, anxiolytics, or a
combination of both groups in the treatment of IBS, many
other pharmacological agents with similar anxiolytic and/or
antidepressant properties have recently been shown to mod-
ulate stress-induced visceral hyperalgesia in animal models
[66]. Among these agents, opioidergic agents, cannabi-
noid receptor 1 (CB1), beta-3 adrenergic and somatostatin
receptors agonists, N-methyl-D-aspartate (NMDA), CRF1
and cholecystokinin receptor antagonists give encouraging
results.
As visceral hypersensitivity is a proposed etiological
factor in IBS, as mentioned above, one way to improve a
suﬀerer’s symptom might be to modulate pain receptors in
the GI tract. Pregabalin and gabapentin, drugs believed to
inhibit pain via the alpha-2-deta-subunits of voltage gated
calcium channels, have both been studied in small single-
center RCTs [67, 68]. Pregabalin was more eﬀective than
a placebo, in terms of increasing the sensory thresholds
for perception of rectal distension, desire to defecate, and
rectal pain, and also demonstrated a trend towards an
improvement in average daily pain scores during 3 weeks of
therapy [67]. Patients treated with gabapentin demonstrated
significantly increased rectal compliance, as well as higher
sensory thresholds for bloating, discomfort, and pain during
a 5-day treatment period [68].
The eﬃcacy of agonists to the kappa-opioid receptors
has also been studied in IBS. After a 100-mg intravenous
infusion of fedotozine, thresholds to first perception of
colonic distension and pain were significantly increased
compared with placebo [69]. A single dose of asimadoline
led to an increased pain threshold to colonic distension
and significantly reduced the area under the curve of pain
intensity in a crossover RCT conducted in 20 IBS subjects
[70]. However, further large RCTs of the latter drug have been
disappointing [71, 72]. One RCT demonstrated no diﬀerence
in achievement of the primary end-point, average reduction
in pain severity 2 hours after treatment, between asimadoline
and a placebo [72], although in a post-hoc analysis there
appeared to be a benefit in those with an alternating bowel
habit. The second study, conducted in almost 600 IBS
patients, also failed to demonstrate any superiority of the
drug over a placebo when the proportion of months with
adequate relief of IBS pain or discomfort was the primary
outcome (37% with active drug versus 33% with placebo)
[71]. In contrast to the study by Szarka and colleagues, when
a preplanned subgroup analysis was conducted, the drug
appeared significantly more eﬀective than a placebo only in
IBS-D patients (47% versus 20%).
On the other hand, solabegron, a beta-3 adrenergic
agonist, was proposed as a treatment for IBS, based on
the finding of functional beta-3 adrenergic receptors on
enteric neurons [73]. However, solabegron failed to show
any significant eﬀect on human gastrointestinal or colonic
transit [74]. A preliminary report of a clinical trial showed
that solabegron, 200mg b.i.d., led to a statistically significant
increase in the proportion of female subjects (P = 0.019)
and possibly subjects of both genders (P = 0.06) achieving
adequate relief from IBS-related pain and discomfort, as
compared with a placebo. There were also improvements
in pain scores and the number of pain-free days but
(consistent with transit results) no significant changes in
bowel symptoms [75].
NMDA receptors are involved in the induction and
maintenance of central sensitization during pain states and
may also medicate peripheral sensitization and visceral pain.
NMDA receptors are composed of NR1, NR2 (A, B, C and
D), and NR3 (A and B) subunits, which determine the
functional properties of native NMDA receptors. Among
NMDA receptor subtypes, the ones containing the NR2B
subunit appear particularly important for nociception,
thereby, suggesting that NR2B-selective antagonists may be
useful in the treatment of chronic pain syndromes [58, 76].
Dextromethorphan is a noncompetitive NMDA receptor
antagonist that is widely used as an antitussive agent.
Gastroenterology Research and Practice 5
In studies conducted on animals, it has been shown to
prevent neuronal damage and modulate pain sensation via
noncompetitive antagonism of excitatory amino acids. It has
proved useful in the treatment of pain in patients with cancer
[77]. Somatic heat hyperalgesia has been reported to be
associated with increased intestinal permeability in patients
with IBS [78]. A subset of IBS patients, but not controls,
showed temporal summation of pain in response to a series
of six noxious heat pulses. In this setting, perceived intensity
of second pain (wind-up) markedly increases with each
successive heat pulse. IBS patients who demonstrated tem-
poral summation of pain received 60mg of dextromethor-
phan or 50mg of benadryl in a randomized, double-
blind fashion to block wind-up pain. Temporal summation
of pain was blocked more eﬀectively by dextromethor-
phan, an NMDA receptor antagonist, than by benadryl
[79].
Regarding the eﬃcacy of cholecystokinin receptor antag-
onist, the eﬀect of dexloxiglumide, a CCK-1 receptor
antagonist, has been studied in female IBS-C patients
[80]. However, the drug had no overall eﬀect on colonic
transit time. Despite this, the proportion of patients with
satisfactory relief of their IBS symptoms was higher with
dexloxiglumide than with a placebo (39% versus 11%),
although this diﬀerence was not statistically significant.
Similarly, pexacerfont, a CRF-1 receptor antagonist, has
been evaluated in women with IBS-D [81]. This drug had no
eﬀect on orocecal transit time, stool frequency or consistency,
or subjective IBS symptoms, including pain and bloating.
Lastly, a study investigating the eﬀect of a slow-release
preparation of octreotide on rectal sensitivity and symptoms
in IBS patients, although showing an increased threshold
of first rectal sensation and improved stool consistency,
highlighted the fact that long-term treatment with this agent
had no visceral analgesic eﬀect and failed to improve IBS
symptoms [82].
In Tables 1 and 2 are showed, respectively, current and
novel psychopharmacological approaches for the treatment
of IBS.
5. Psychological Interventions
Although the etiology of IBS has not been elucidated com-
pletely, it is widely accepted that this entity is multifactorial,
with external stress and environmental factors playing some
role [83]. Since treatment with diet or pharmacological
agents alone has been partially successful, psychological
interventions have been instituted with promising eﬃcacy.
[84].
A broad range of evidence-based mind-body inter-
ventions including psychodynamic therapy, cognitive-
behavioral therapy (CBT), hypnotherapy, relaxation
exercises, or mindfulness meditation has been shown to
amend stress coping strategies, both at a cognitive level
(catastrophic or self-defeating thoughts) and at a behavioral
level (problem solving, especially interpersonal problems)
[85, 86]. The symptomatic improvement appears to result
from the modulation of stress response, autonomic nervous
system balance restoration, and changes in the brain
activation pattern in response to visceral stimuli [87].
Interestingly, the symptom course and relapse pattern
after psychotherapy seem to diﬀer from those after drug
treatment [88]. In one trial, 101 IBS patients received
standard medical therapy with or without psychotherapy
administered over a 3-month period [89]. During the 3-
month intervention period, the improvement was greater
in the psychotherapy group than that in the control
group. Subsequently, in a 1-year treatment-free followup,
the improvement continued in the psychotherapy group,
whereas symptoms recurred in the controls, who returned
to their initial state [89].
With regard to diﬀerent psychotherapy approaches, more
than 22 trials have been published [47, 90], substantially
demonstrating that psychotherapy not only improves psy-
chological symptoms (as anxiety and depression), but also GI
symptoms directly [91].Many of these studies were, however,
not selected for meta-analysis because of specific diﬃculty
in controlling unspecific eﬀects. A true “placebo treatment”
for such studies is not available and waiting list controls, a
frequently established mode in psychotherapy research, may
be inappropriate for meta-analytic purposes.
Considering these diﬃculties, Ford and coworkers, in
their meta-analysis mentioned above, observed that while
antidepressants are eﬀective in the treatment of IBS, there
are few high-quality studies on the use of psychological
therapies in IBS; nevertheless, they showed that a range of
diﬀerent psychological therapies was able to significantly
reduce physical symptoms in patients with IBS, with studies
on CBT providing the greatest evidence [47].
Similarly, in another systematic review and meta-analysis
performed by the Cochrane Library [90], the authors
concluded that psychological therapies may be superior to
the usual care at the end of treatment, although the clinical
significance of this benefit is doubtful, considering that
the results of the meta-analysis should be interpreted with
caution, due to the low methodological quality of the studies
included, variability in outcome definitions and small sample
size, which resulted in considerable heterogeneity.
According to the authors, psychological therapies in
general are not superior to placebos, and the long-term sus-
tainability of the treatment eﬀects of psychological therapies
is questionable [90].
In this situation, self-managed support is challenging.
A recent systematic review performed by Dorn about
self-management support interventions for IBS, including
eleven studies, emphasizes the fact that self-management
is an essential component of care for IBS [92]. It requires
providers to help their patients understand their condi-
tions, manage their own medications, deal with emotional
sequelae, develop problem-solving skills, and learn how to
find and utilize resources. However, many studies included
in this review were of subpar quality, and most of the
interventions did not seem feasible for “real world” clinical
practice, suggesting that the key challenge for improving self-
management in IBS is to develop practical self-management
interventions that can be applied across various clinical
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Table 1: Current psychotropic drugs used for treatment of irritable bowel syndrome.
Classes of drugs Mechanism of action Therapeutic issues
Antidepressants (SSRIs, TCADs, SNRIs) Neurotransmitters reuptake inhibitors
Reduction of abdominal pain; limited data about
safety and tolerability
Benzodiazepines Enhancement of GABA inhibitory eﬀect
Limited use; risk of tolerance and rebound with-
drawal; lack of reliable antidepressant eﬃcacy
Atypical Antipsychotics (Quetiapine)
Receptorial antagonism with dopamin-
ergic (D2) and serotoninergic (5-HT2)
receptors
Possible use only in patients with severe psy-
chiatric comorbidities; lacking data and evi-
dence about eﬃcacy and safety in irritable bowel
syndrome
SSRIs: selective serotonin reuptake inhibitors. TCADs: trycyclic antidepresants. SNRIs: serotonin norepinephrine reuptake inhibitors. 5-HT: 5-
hydroxytriptamine.
Table 2: Novel psychotropic agents used for the treatment of irritable bowel syndrome.
Classes of drugs Mechanism of action Therapeutic issues
Corticotrophin releasing factor antagonists Modulation of corticoid system Limited use, under investigation
Opioidergic agents Modulation of visceral nociception Limited central side eﬀects, good eﬃcacy
Cholecystokinin receptor antagonists
Modulation of cholecystokinin
pathways
Limited use, under investigation
Somatostatin analogues Inhibition of rectal sensitivity Limited use and eﬃcacy, under investigation
Beta-3 adrenergic agonists Modulation of beta-3 adrenergic system Limited eﬃcacy in bowel symptoms
N-methyl-D-aspartate antagonists Central and peripheral analgesics
Limited eﬃcacy, restricted on abdominal
pain
settings, and then to test them in well-designed clinical trials
[92].
CBT is considered the most well-studied psychological
treatment for IBS [93], but one limitation is that CBT is
rarely available in routine care of IBS [94]. Several factors
contribute to this, for example, the lack of trained therapists,
high costs of delivering the treatment, and the practical
diﬃculties for patients of scheduling weekly visits at a clinic.
Interestingly, several researchers have conducted studies
investigating CBT for IBS where participants had therapist
contact via the internet (ICBT), defined as a web-based
bibliotherapy with an online therapist contact: ICBT proved
to be a promising cost-eﬀective treatment modality for IBS as
it can be oﬀered to IBS patients on a much larger scale than
conventional psychological treatments [95].
In the setting of CBT, a study performed by Lackner
and coworkers sought to determine whether the therapeu-
tic phenomenon of rapid response characterizes patients
undergoing CBT for IBS; in this study, performed on 71
patients, 30% of CBT-treated patients achieved RR by week
4 of treatment and 90–95% of patients with rapid response
maintained gains at immediate and 3 month followup.
The authors concluded that rapid response is a potentially
important prognostic outcome indicator that has important
implications for developing step care approaches for IBS
patients [96].
Another study, performed by Reme and coworkers,
wanted to examine predictors of treatment outcome after
CBT and antispasmodic treatment for patients with IBS in
primary care at 12 months after treatment ended. In this
study, lower levels of psychological distress (anxiety and
depression) at baseline predicted a good outcome in the
mebeverine group, but not in the mebeverine + CBT group;
in the adjusted model for the mebeverine + CBT group
less adaptive IBS related behavioral coping predicted a good
outcome [97].
With regard to hypnosis, an important observation has
been made by researchers working on its role in treating
IBS [98]. Tan et al. and Wilson et al., respectively, observed
in their systematic reviews (in spite of both comprising
uncontrolled trials) that hypnotherapy was eﬀective in the
management of IBS; however, these authors also recom-
mended better quality trials [99, 100].
A Cochrane review and meta-analysis, including four
studies, suggests a beneficial eﬀect of hypnosis in the short
term, although this result needs to be interpreted with
caution, due to the small size andmethodological flaws of the
studies included, but emphasizes that hypnotherapy appears
to be a safe intervention that could be tried in patients who
fail standard medical therapy [101].
Curiously, the IMAGINE study [102] showed that if
hypnotherapy is eﬀective and if there is no diﬀerence in
eﬃcacy between individual and group hypnotherapy, this
group form of treatment could be oﬀered to more IBS
patients, at lower costs.
Another interesting study performed by Lindfors and
coworkers showed how gut-directed hypnotherapy is an
eﬀective treatment alternative for patients with refractory
IBS, but the eﬀectiveness is lower when therapy is given
outside highly specialized research centers [103].
With regard to the evidence about psychodynamic
therapy, one central problem of all psychodynamic therapy
interventions is their poor controllability, as they are diﬀer-
ent from CBT trials: they are not made up of identifiable
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modules that can be controlled, for example, by dismissing
them in the control group, and finally it is less well
standardized in terms of its performance (duration, setting)
[104]. In a recent systematic review, only two large-scale
psychodynamic therapy interventions yielded an odds ratio
of 2.92 (1.76–4.83) [105].
Similarly, few data are available about meditation and
reflexology. In a small pilot study performed on 16 patients
on whom a medication program was tested and who were
asked to practice it regularly at home, a significant improve-
ment was seen in flatulence, bloating, and diarrhea, and
clinical responses were sustained with continued meditation
at 1-year followup [106]; however, it is unclear whether
these results demonstrate a genuine therapeutic eﬀect or a
placebo eﬀect. With regard to reflexology, only a small single-
blind trial has been conducted, involving 34 IBS patients, in
a primary care setting, randomized either to a reflexology
foot massage or to a nonreflexology foot massage control
group; no significant diﬀerence was seen in bowel symptoms
between the groups [107].
To date, it is not yet clear if psychosocial therapies are
more eﬀective than psychotropic agents in the management
of IBS; although some researchers claim the superiority of
psychological treatments over antidepressants in terms of
long-term reduction in health-care costs [108], there is a
scarcity of studies comparing the two diﬀerent treatment
modalities of IBS.
6. Conclusions
IBS is a chronic relapsing condition, sometimes associated
with significant disability, and with a considerable financial
burden for the health service, due to the consumption
of resources including physician time, investigations, and
costs of treatment [6]. The presence of clinically significant
psychiatric symptoms in patients with IBS is an indication
for psychotropic agents, especially when stress reactivity is
observed [45]. Indeed, antidepressants are eﬀective treat-
ments in IBS, probably as a result of their antinociceptive
eﬀects, although additional eﬀects on GI transit may be
contributory [6]. Whether any beneficial eﬀect occurs via
the treatment of coexistent depression remains unclear, but
there was no correlation between depression scores and
improvements in IBS symptoms in the studies identified
in the meta-analyses that examined this issue [47], also
considering that, in the case of TCADs, the doses employed
for treating IBS were generally much lower than those used
for the treatment of depression [6].
The paucity of data available on the safety and tolerability
of psychotropic agents in IBS limits their usage to second-line
therapy, according to current IBS management guidelines
[48, 109], thus, confirmation of existing practices with
randomized, controlled trials is strongly needed.
With regard to psychological therapies, it is not yet
clear if they are more eﬀective than psychotropic agents in
the management of IBS. The present evidence show that
psychological therapies may be superior to the usual care
at the end of treatment, although the clinical significance
of this benefit is doubtful and the long-term sustainability
of the eﬀects of these treatments is questionable; further
studies should focus on the longer term eﬀects and placebos,
following current recommendations for IBS treatment trials.
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